Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Tarek Aly

Psychiatry Daytona Beach, FL Medical Doctor

NPI 1225419559 CMS profile 7919100

3500 W International Speedway Blvd, Daytona Beach, FL 32124

Open in the dashboard

General payments

$83,081

278 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tarek Aly of Daytona Beach, FL is reported in the CMS Open Payments database as having received $83,081 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,796 24
2024 General $19,510 56
2023 General $26,726 64
2022 General $9,328 66
2021 General $17,659 64
2020 General $63 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tarek Aly
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Tarek Aly were reported at $9,796. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Tarek Aly Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $63 $119 $36–$372 $114
2021 $17,659 $143 $43–$576 $132
2022 $9,328 $153 $50–$590 $149
2023 $26,726 $170 $56–$651 $160
2024 $19,510 $179 $57–$673 $164
2025 $9,796 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $65,791 116 payments
  2. Neos Therapeutics, LP $11,510 45 payments
  3. Aytu BioScience, Inc $3,703 6 payments
  4. Corium, Inc. $389 26 payments
  5. Alkermes, Inc. $317 12 payments
  6. Otsuka America Pharmaceutical, Inc. $205 10 payments
  7. Lundbeck LLC $204 10 payments
  8. ITI, Inc. $196 11 payments
  9. Supernus Pharmaceuticals, Inc. $148 8 payments
  10. Tris Pharma Inc $142 8 payments
  11. Other $476 26 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $73,725 37 payments
  2. Food and Beverage $4,893 234 payments
  3. Travel and Lodging $4,448 6 payments
  4. Education $15 1 payment
Products named General payments · program years 2020–2025
  1. VRAYLAR Neuroscience $56,235 106 payments
  2. Adzenys XR-ODT $11,310 43 payments
  3. COTEMPLA XR-ODT $10,974 22 payments
  4. VRAYLAR Neuroscience $9,556 10 payments
  5. ZolpiMist $3,873 9 payments
  6. Azstarys $389 26 payments
  7. ARISTADA Cns $288 10 payments
  8. ARISTADA Cns $288 10 payments
  9. ARISTADA Cns $238 7 payments
  10. ARISTADA Cns $238 7 payments
  11. Other $1,971 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

635

Median for Psychiatry & Neurology: 100

Drug cost

$37,580

Median for Psychiatry & Neurology: $2,986

Branded share of claims

30.1%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 21 $25,901
Lamotrigine Er Lamotrigine Brand 28 $2,471
Vilazodone Hcl Generic 19 $1,386
Guanfacine Hcl Er Guanfacine Hcl Brand 47 $1,168
Duloxetine Hcl Generic 53 $1,056
Trazodone Hcl Generic 50 $726
Escitalopram Oxalate Generic 50 $681
Bupropion Xl Bupropion Hcl Brand 35 $581
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 19 $502
Clonazepam Generic 54 $480

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $18,956
$18,956 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $68
$68 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $65
$65 — —
Azstarys
  • Corium, Inc. $64
$64 — —
LOREEV XR
  • Almatica Pharma LLC $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record